共 41 条
- [36] REAL-WORLD VISUAL OUTCOMES IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION RECEIVING INTRAVITREAL AFLIBERCEPT AT FIXED INTERVALS AS PER UK LICENSE [J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 45 : 135 - 136
- [38] TIME COURSE OF VISUAL ACUITY CHANGES WITH INTRAVITREAL AFLIBERCEPT (IVT-AFL) OR MACULAR LASER PHOTOCOAGULATION IN PATIENTS WITH DIABETIC MACULAR EDEMA (DME): OUTCOMES FROM THE VIVID-DME AND VISTA-DME CLINICAL TRIALS [J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 42 : 13 - 13
- [39] Similar real-world two-year visual acuity gains in treatment-naive patients with diabetic macular oedema treated with a loading dose of three initial monthly injections versus less intensive regimens of intravitreal anti-vascular endothelial growth factor [J]. ACTA OPHTHALMOLOGICA, 2021, 99 (07) : E1248 - E1249
- [40] Best corrected visual acuity(BCVA) and central macular thickness (CMT) outcomes after fluocinolone acetonide intravitreal implant (FAc) injection in multitreated chronic diabetic macular edema (DME) patients. Efficacy in a real life setting in the United States [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)